BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36190344)

  • 1. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study.
    Giollo A; Zen M; Larosa M; Astorri D; Salvato M; Calligaro A; Botsios K; Bernardi C; Bianchi G; Doria A
    Rheumatology (Oxford); 2023 Jun; 62(6):2083-2089. PubMed ID: 36190344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes.
    David P; Di Matteo A; Hen O; Dass S; Marzo-Ortega H; Wakefield RJ; Bissell LA; Nam J; Mankia K; Emery P; Saleem B; McGonagle D
    Arthritis Rheumatol; 2024 Apr; 76(4):510-521. PubMed ID: 38059326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
    Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
    Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis.
    Yoshii I; Sawada N; Chijiwa T
    Rheumatol Int; 2022 Nov; 42(11):1947-1954. PubMed ID: 35410410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
    Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
    Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease.
    Leon L; Madrid-Garcia A; Lopez-Viejo P; González-Álvaro I; Novella-Navarro M; Freites Nuñez D; Rosales Z; Fernandez-Gutierrez B; Abasolo L
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36889800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Aug; 60(8):3778-3788. PubMed ID: 33331946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
    Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
    Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.
    Tan Y; Buch MH
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study.
    Michitsuji T; Fukui S; Morimoto S; Endo Y; Nishino A; Nishihata S; Tsuji Y; Shimizu T; Umeda M; Sumiyoshi R; Koga T; Iwamoto N; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Ohtsubo H; Takaoka H; Hamada H; Tsuru T; Nawata M; Arinobu Y; Hidaka T; Tada Y; Kawakami A; Kawashiri SY
    Scand J Rheumatol; 2024 Mar; 53(2):123-129. PubMed ID: 38085537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.
    Garcia-Salinas R; Sanchez-Prado E; Mareco J; Ronald P; Ruta S; Gomez R; Magri S
    Rheumatol Int; 2023 Oct; 43(10):1821-1828. PubMed ID: 37269430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.
    Roodenrijs NMT; Welsing PMJ; van der Goes MC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Oct; 60(10):4681-4690. PubMed ID: 33502493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis.
    Philippoteaux C; Marty-Ane A; Cailliau E; Labreuche J; Philippe P; Cortet B; Paccou J; Flipo RM; Letarouilly JG
    Semin Arthritis Rheum; 2023 Dec; 63():152275. PubMed ID: 37852155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
    Watanabe R; Ebina K; Gon T; Okano T; Murata K; Murakami K; Maeda Y; Jinno S; Shirasugi I; Son Y; Amuro H; Katayama M; Hara R; Hata K; Yoshikawa A; Yamamoto W; Tachibana S; Hayashi S; Etani Y; Katsushima M; Fukumoto K; Yamada S; Hashimoto M
    Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38724245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.
    Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ohmura K; Ito H; Matsuda S
    Immunol Med; 2022 Mar; 45(1):35-44. PubMed ID: 34033729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"].
    Gordeev AV; Matyanova EV; Galushko EA
    Ter Arkh; 2023 Jul; 95(5):380-385. PubMed ID: 38158989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis.
    Buch MH; Eyre S; McGonagle D
    Nat Rev Rheumatol; 2021 Jan; 17(1):17-33. PubMed ID: 33293696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; van Oorschot EPC; Nikiphorou E; Nijhof NC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM; Geenen R
    Rheumatology (Oxford); 2021 Nov; 60(11):5105-5116. PubMed ID: 33560301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.